A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subjects With Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs TAK 831 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Takeda
- 04 Sep 2019 Planned End Date changed from 12 Aug 2019 to 16 Jan 2020.
- 04 Sep 2019 Planned primary completion date changed from 12 Aug 2019 to 16 Jan 2020.
- 18 Jun 2019 Status changed from active, no longer recruiting to recruiting.